BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target

BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 212.0% from the Sep 25 close of $57.06.Key takeaways from the analyst noteStrong Clinical Data for REZPEG: Nektar Therapeutics has demonstrated a strong safety and ef…